{
    "root": "303e9e2e-26e7-c444-e063-6394a90a3b62",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Duloxetine",
    "value": "20250313",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)",
            "code": "87Y6436BKR"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "DULOXETINE HYDROCHLORIDE",
            "code": "9044SC542W"
        }
    ],
    "indications": "duloxetine delayed-release capsules indicated treatment : major depressive disorder adults generalized anxiety disorder adults pediatric patients 7 years age older diabetic peripheral neuropathic pain adults fibromyalgia adults pediatric patients 13 years age older chronic musculoskeletal pain adults additional pediatric information approved eli lilly company , inc. \u2019 cymbalta ( duloxetine ) delayed-release capsules . however , due eli lilly company inc. \u2019 marketing exclusivity rights , product labeled pediatric information .",
    "contraindications": "take duloxetine delayed-release capsules daily , without food . swallow whole ; crush , chew , open capsule ( 2.1 ) indication starting dose target dose maximum dose mdd ( 2.2 ) 40 mg/day 60 mg/day acute treatment : 40 mg/day ( 20 mg twice daily ) 60 mg/day ( daily 30 mg twice daily ) ; maintenance treatment : 60 mg/day 120 mg/day gad ( 2.3 ) adults geriatric pediatrics ( 7 17 years age ) 60 mg/day 30 mg/day 30 mg/day 60 mg/day ( daily ) 60 mg/day ( daily ) 30 60 mg/day ( daily ) 120 mg/day 120 mg/day 120 mg/day dpnp ( 2.4 ) 60 mg/day 60 mg/day ( daily ) 60 mg/day fm ( 2.5 ) adults pediatrics ( 13 17 years age ) 30 mg/day 60 mg/day ( daily ) 60 mg/day chronic musculoskeletal pain ( 2.6 ) 30 mg/day 60 mg/day ( daily ) 60 mg/day discontinuing duloxetine delayed-release capsules : gradually reduce avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "maois intended treat psychiatric disorders duloxetine delayed-release capsules within 5 days stopping treatment duloxetine delayed-release capsules contraindicated increased risk serotonin syndrome . duloxetine delayed-release capsules within 14 days stopping maoi intended treat psychiatric disorders contraindicated [ ( 2.8 ) ( 5.4 ) ] . starting duloxetine delayed-release capsules patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.9 ) ( 5.4 ) ] .",
    "indications_original": "Duloxetine delayed-release capsules are indicated for the treatment of:\n                  \n                     Major depressive disorder in adults\n                     Generalized anxiety disorder in adults and pediatric patients 7 years of age and older\n                     Diabetic peripheral neuropathic pain in adults\n                     Fibromyalgia in adults and pediatric patients 13 years of age and older\n                     Chronic musculoskeletal pain in adults\n                  \n                  \n                     Additional pediatric use information is approved for Eli Lilly and Company, Inc.\u2019s CYMBALTA (duloxetine) delayed-release capsules. However, due to Eli Lilly and Company Inc.\u2019s marketing exclusivity rights, this drug product is not labeled with that pediatric information.",
    "contraindications_original": "Take duloxetine delayed-release capsules once daily, with or without food. Swallow whole; do not crush, chew, or open capsule ( 2.1 ) Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 40 mg/day to 60 mg/day Acute Treatment: \u00a0\u00a0\u00a0\u00a0\u00a040 mg/day (20 mg twice daily) to \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a060 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 120 mg/day GAD ( 2.3 ) Adults Geriatric Pediatrics (7 to 17 years of age) 60 mg/day 30 mg/day 30 mg/day 60 mg/day (once daily) 60 mg/day (once daily) 30 to 60 mg/day (once daily) 120 mg/day 120 mg/day 120 mg/day DPNP ( 2.4 ) 60 mg/day 60 mg/day (once daily) 60 mg/day FM ( 2.5 ) Adults and Pediatrics (13 to 17 years of age) 30 mg/day 60 mg/day (once daily) 60 mg/day Chronic Musculoskeletal Pain ( 2.6 ) 30 mg/day 60 mg/day (once daily) 60 mg/day Discontinuing duloxetine delayed-release capsules: Gradually reduce dosage to avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "adverseReactions_original": "The use of MAOIs intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. The use of duloxetine delayed-release capsules within 14 days of stopping an MAOI intended to treat psychiatric disorders is contraindicated\n \n  [see\u00a0\n  \n   Dosage and Administration (2.8)and\n  \n   Warnings and Precautions (5.4)]\n \n  .\n\n \n                  Starting duloxetine delayed-release capsules in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n \n  [see\u00a0\n  \n   Dosage and Administration (2.9)and\n  \n   Warnings and Precautions (5.4)]\n \n  ."
}